New patient survey highlights need for more action to help severe asthma patients gain control of their disease

NovartisNovartis announced the results of a new survey of 904 severe asthma patients, presented for the first time at the European Academy of Allergy and Clinical Immunology (EAACI) Congress[1]. Data from the 'Still Fighting for Breath' survey demonstrate that, despite the widespread availability of oral and inhaled treatments, asthma still places a huge burden on the personal and professional lives of those living with the disease in Europe.

The new survey revealed that high levels of uncontrolled disease still exist amongst adults and children with severe asthma. Asthma attacks (also known as exacerbations) were reported to be extremely common. Nearly three quarters (74%) of patients surveyed experienced an attack serious enough to have required treatment from a healthcare professional in the emergency room, ambulance or at home. Furthermore, almost a third (32%) of patients experienced three or more exacerbations during this time period. While a majority of patients (54%) experiencing an exacerbation physically recovered after treatment within 24 hours, these patients often remained psychologically affected for a prolonged period of time after the exacerbation, with almost a fifth of them (19%) reporting effects persisting over a week[1].

Importantly, this new research found a significant discrepancy between "perceived" versus "real life" asthma control. Specifically, nearly half (46%) of the patients surveyed had self-estimated themselves as being "controlled", which is a marked contrast to the 6% of patients that were actually deemed as "controlled" according to the Global Initiative for Asthma (GINA) clinical guidelines. This discrepancy may be a limiting factor in patients seeking support to control their condition.

"The results from this new survey are important as the data demonstrate that too many patients in Europe are living with the daily burden of uncontrolled severe asthma. As such, this patient population may be significantly under-served", said Professor Antonella Muraro, one of the authors of the survey. "More needs to be done and the first step is to bridge the gap between the perceptions of 'good' control vs reality, among people with asthma. We need to focus greater efforts on empowering and educating those living with asthma to fight for better outcomes and to help them achieve a life unrestricted by their condition."

In addition to revealing the high levels of uncontrolled disease, the survey also underscored the disruptive impact that living with severe asthma has on the lives of patients. Nearly nine out of ten patients reported that their condition impacted their daily living (88%) and 84% reported that it impacted physical activities, with almost all patients (97%) reporting it disturbed their sleep. Significantly, half of the patients surveyed believe their professional lives are negatively impacted by their condition.

In response to the survey findings Novartis is launching a new patient engagement program, entitled Billion Breaths. The program will encourage people to set activity goals and provide advice and support to help them achieve a life less restricted by asthma [https://www.youtube.com/watch?v=kniyOgnpQr4 (link is external)].

About the asthma impact study in Europe
The study enrolled 904 adult patients (>=18 years) and children (6-17 years old) suffering from severe persistent asthma. It spanned several countries, including the United Kingdom (n=190), Germany (n=170), France (n=170, Italy (n=116), Spain (n=115) and Portugal (n=30).

Data were collected through an online survey between July 12 and October 31 2016. Data for adolescent and pediatric patients were obtained through caregivers. Collection and analysis of all data was completed by GFK Health on behalf of Novartis.

The severe asthmatic patients in this survey were diagnosed by respiratory physicians (38%), general practitioners (33%), allergists (23%) and pediatricians (5%). On average, adults were diagnosed with the disease 15 years ago, adolescents seven years old and pediatrics three years ago. According to the patients' understanding 49% considered themselves to have non-allergic asthma (no additional tests were performed).

About asthma
Asthma is a global health problem[2] affecting an estimated 300 million people worldwide[3]. It is a common long-term condition that can cause coughing, wheezing, chest tightness and breathlessness.

There is no cure for asthma and treatment focuses on symptom relief[3]. Asthma symptoms can either gradually or suddenly become worse. This is commonly referred to as an "asthma attack" or "exacerbation". Severe exacerbations may require hospital treatment and can be life- threatening[4]. However, when appropriate treatment is instituted, asthma can be controlled without symptoms.

There are many different types of asthma. Severe asthma is a specific form of asthma that requires specialist care and support. It affects approximately 5% of people with the condition. A patient with severe asthma may have breathing difficulties and is also at risk of serious exacerbations[5].

Approximately 87% of severe asthma patients have taken oral corticosteroids (OCS), for a reported average period of 20 days in the last six months[1]. The updated 2017 GINA guidelines for asthma management state that patients should be provided with written guidance on when/how to commence OCS treatment, typically a short course (40mg/day for 5-7 days), and should also be advised of the potential side effects that may occur when taking OCS[2].

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

1. Katsaounou P, Conde L G, Kroegel C et al. The challenges of living with severe asthma in Europe. Abstract #858 presented at EACCI Congress 2017
2. Global Strategy for Asthma Management and Prevention (2017). http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/ [Accessed March 2017]
3. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach, 2007. http://www.who.int/gard/publications/GARD%20Book%202007.pdf. [Accessed April 2017]
4. NHS Choices - Asthma. http://www.nhs.uk/conditions/Asthma/Pages/Introduction.aspx [Accessed April 2017]
5. Asthma UK, Severe asthma and difficult to control asthma. https://www.asthma.org.uk/advice/understanding-asthma/types/severe-asthma/ [Accessed March 2017]

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...